Boehringer Ingleheim updates on pipeline; enters diabetes market for first time

27 October 2008

German drugmaker Boehringer Ingleheim has reported on its pipeline at its second international R&D press conference, unveiling three unique oral anti-diabetic compounds in Phase II and III and so entering the diabetes sector for the first time.

"Our research into new treatment options for patients with type 2 diabetes began in 2001 and is now bearing fruit. This is particularly important since, despite a variety of treatment options available today, patients continue to struggle with tolerability," said Klaus Dugi, vice president of medical affairs.

Three new diabetes candidates in Phase II/III

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight